March 10, 2018 9:22am

Q4 and FT 17 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene and regenerative therapy's companies.

The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot!

By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.

 


COMPANY SYMBOL NET INCOME Q4/17 LOSS Q4/17 LPS Q4/17 CASH 
Aduro Biotech, Inc. ADRO  

-$26.1 M

$91.9 M (FY17)

-$0.34

-$1.26

$349.7 M
Applied Genetic Technologies AGTC   -$5.2 M (Q2) -$0.29 $119.7 M
Asterias Biotherapeutics AST  

-$5.5 M

-$28.4 M (FY17)

-$0.12

-$0.56

$21.6 M
Athersys, Inc. ATHX  

-$13.1 M

-$32.2 M (FY17)

-$0.11

-$0.29

$29.3 M

+$31.1 M (3/13)

Adverum Biotechnologies, Inc. ADVM  

-$14.5 M

-$56.1 M (FY17)

-$0.32

-$1.29

$190.5 M
AxoGen, Inc. AXGN  

-$2.5 M

-$10.4 M (FY17)

-$0.07

-$0.31

$36.5 M
Bellicum Pharmaceuticals, Inc. BLCM  

-$21.9 M

-$91.8 M (FY17)

-$0.66

-$2.89

$106.5 M
BioLife Solutions, Inc. BLFS  

-$664 K

-$1.728 M (FY17)

-$0.05

-$0.21

$6.6 M
Biostage, Inc. BSTG  

-$1.2 M

-$11.9 M (FY17)

-$0.61

-$6.63

$4 M
BioTime, Inc. BTX  

-$71,9 M

-$20 M (FY17)

-$0.58

-$0.17

$38.2 M
bluebird bio BLUE  

-$117.2 M

-$335.6 M (FY17)

-$2.52

-$7.71

$1.6 B
Brainstorm Cell Therapeutics Inc. BCLI  

N/A

-$.95 M

N/A

-$0.26

$7.75 M
Caladrius Biosciences. CLBS  

-$4 M

-$16.2 M

-$0.40

-$1.78

$60.1 M
Capricor CAPR +$12.3 M

 

-$2.4 M

+$0.42

-$0.09

$14.1 M
Cellectis SA CLLS  

-$16.4 M

-$50.4 M (FY17)

-$0.46

-$1.41

$297 M
Cesca Therapeutics, Inc KOOL   -$2.3 M (Q2) -$0.23 $3.5 M
Cytori Therapeutics, Inc. CYTX  

-$4.3 M

-$22.64 M (FY17)

-$0.10

-$0.82

$9.6 M
Fate Therapeutics, Inc. FATE  

-$12.4 M

-$41.9 M (FY17)

-$0.29

-$1.02

$100.9 M
Fibrocell Science, Inc. FCSC  

Q4 Not disclosed

-$20.8 M (FY17)

N/D

-$1.23

$17.4 M
Histogenics Corporation HSGX  

-$6.1 M

-$22.5 M (FY17)

-$0.26

-$0.99

$8 M

+$14.9 (1/18)

ImmunoCellular Therapeutics, Ltd. IMUC  

-$4.31 M

-$17.7 M (FY17)

-$0.01

-$1.23

$6.6 M
International Stem Cell ISCO  

Q4 Not Disclosed

-$6.06 M (FY17)

N/A

-$1.46

$304 K
Intrexon Corporation XON  

-$27.3 M

-$117 M (FY17)

-$0.23

-$0.98

$74.4 M
Mesoblast Limited MESO   -$13.7 M (Q2) -$2.91 $47.4 M
MiMedx Group, Inc MDXG        
Neuralstem, Inc.  CUR  

Q Not disclosed

-$15.7 M

N/D

-$1.20

$11.7 M
Northwest Biotherapeutics, Inc. NWBO   -$73 M (FY17) -$0.31 $11.7 M
Organovo Holdings, Inc. ONVO   -$7.8 M (Q3) -$0.08 $47.3 M
Osiris Therapeutics, Inc. OSIR        
Pluristem Therapeutics, Inc. PSTI   -$8.22 M -$0.08 $15.6 M
ReNeuron Group PLC RENE.L        
Regenxbio RGNX  

-$16 M

-$73.2 M (FY17)

-$0.51

-$2.45

$176 M
Sangamo Biosciences, Inc. SGMO  

-$13.1 M

$54.6 M (FY17)

-$0.15

-$0.70

$244.6 M
Spark Therapeutics, Inc. ONCE   -$253.5 M (FY17) -$7.63

$540.2 m

$105 M (1/18)

Stemline Therapeutics, Inc. STML  

-$21.7 M

-$67.8 M

-$0.93

-$2.94

$66.2 M

+$55.5 M in new raise

uniQure N.V. QURE  

Not Disclosed (ND)

-$79.3 (FY17)

ND

-$2.94

$159.4 M
Verastem, Inc. VSTM  

Not disclosed (ND)

-$67.8 M (FY17)

ND

-$1.76

$86.7 M
Vericel Corporation VCEL +$300 K

 

-$17.4

+$0.01

-$0.53

$26.9 M
VistaGen Therapeutics, Inc. VTGN   -$3.5 M (Q3) -$0.25 $13 M